zł1,132.00
0.35%
Warsaw, Oct 16, 04:06 pm CEST. Closed.
ISIN
SI0031102120
Symbol
KRK

Krka Stock price

zł1,132.00
-6.00 0.53% 1M
+90.00 8.64% 6M
+272.00 31.63% YTD
+288.00 34.12% 1Y
+620.00 121.09% 3Y
+622.00 121.96% 5Y
+855.70 309.70% 10Y
+922.00 439.05% 20Y
Warsaw, Closing price Fri, Oct 16 2026
+4.00 0.35%
ISIN
SI0031102120
Symbol
KRK
Sector

AI Insights on Krka Insights AI Insights on Krka

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Krka a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
zł42.0b
Enterprise Value
zł84.5b
Net debt
zł42.5b
Cash
zł83.1b
Shares outstanding
2.5b
Valuation
P/E
1,029.1
P/S | estimate
0.2 | 0.1
EV/Sales | estimate
0.3 | 0.3
EV/FCF | ex SBC
negative | -
P/B
0.7
Dividends
DPS
zł35.09
Yield 1Y | 5Y
3.1% | 4.5%
Growth 1Y | 5Y
9.3% | 13.2%
Payout 1Y | 3Y
4,719.1% | 2,162.3%
Increased
2 Years
Financials
Revenue | estimate
zł246.1b | zł284.2b
EBITDA
zł18.2b
EBIT
zł11.7b
Net Income
zł2.8b
Free Cash Flow | ex SBC
zł-27.2b | -
Growth
Revenue | estimate
32.6% | 31.3%
EBITDA
66.8%
EBIT
111.9%
Net Income
508.3%
Free Cash Flow
-26.0%
Margin
Gross
17.6%
EBITDA
7.4%
EBIT
4.7%
Net
1.1%
Free Cash Flow | ex SBC
-11.1% | -
Financial Health
Equity Ratio
12.7%
Return on Equity
3.3%
ROCE
6.6%
ROIC
3.6%
Debt/Equity
2.0
More
EPS
zł1.1
FCF per Share
zł-10.7
Short interest
-
Employees
123k
Rev per Employee
zł1.8m

Krka Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Krka forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Krka forecast:

Buy
92%
Hold
8%

Krka Events

Past Events
AUG
4
Q2 2026 Earnings Call
2 months ago
MAY
8
Q1 2026 Earnings Call
5 months ago
FEB
10
2025 Earnings Call
8 months ago
NOV
5
Koç Holding A.S., Nine Months 2025 Earnings Call, Nov 06, 2025
12 months ago

Financial data from Krka

Jun '26
+/-
%
246,098 246,098
33% 33%
100%
- Direct Costs 202,916 202,916
29% 29%
82%
43,182 43,182
54% 54%
18%
- Selling and Administrative Expenses 31,022 31,022
36% 36%
13%
- Research and Development Expense 776 776
22% 22%
0%
18,186 18,186
67% 67%
7%
- Depreciation and Amortization 6,529 6,529
21% 21%
3%
EBIT (Operating Income) EBIT 11,657 11,657
112% 112%
5%
Net Profit 2,793 2,793
508% 508%
1%

In millions PLN.

Don't miss a Thing! We will send you all news about Krka directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

KRKA dd is a generic pharmaceutical company, which engages in the development, production, marketing, and sale of human and animal health products. It operates through the following geographical segments: European Union, South-East Europe, Eastern Europe, and Other. The European Union segment includes all countries of the European Union. The South-East Europe segment consists of Serbia, Bosnia and Herzegovina, Macedonia, Montenegro, Kosovo, and Albania. The Eastern Europe segment comprises of the Russian Federation and other former Soviet Union countries, excluding the Baltic countries. The company was founded by Boris Andrijanic in 1954 and is headquartered in Novo Mesto, Slovenia.

Head office Slovenia
CEO Mr. Cakiroglu
Employees 122,623
Founded 1954
Website www.koc.com.tr

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today